Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • GenoMax
    Senior Member
    • Feb 2008
    • 7142

    #1

    NGS devices get US-FDA approval

  • austinso
    Member
    • Jun 2012
    • 77

    #2
    Caveat is that it can only handle up to V2 chemistry.

    Comment

    • GenoMax
      Senior Member
      • Feb 2008
      • 7142

      #3
      Not surprising. There will likely be no "user serviceable parts" in MiSeqDX. Approval is for specific version of MCS/chemistry/analysis software.

      This application may need a new purchase i.e. an existing MiSeq probably can't be upgraded to a MiSeqDX.

      Looks like the pages for Molecular Diagnostics are already up: http://www.illumina.com/clinical/diagnostics.ilmn

      Comment

      • austinso
        Member
        • Jun 2012
        • 77

        #4
        In fact, the instrument would be a "downgrade" compared to what is out now from what I understand...the requirement of the FDA approval process that everything must be locked down prior to submission.

        But, while this does open the door to FDA-approved reagents for NGS, there could be ramifications for current LDTs using sequencing given the CLIA vs. FDA ambiguity.

        Comment

        • ymc
          Senior Member
          • Mar 2010
          • 496

          #5
          I presume if you want to make a product out of this MiSeqDX, your interpretation software should also need FDA approval, right?

          Are there any incentive for Foundation Medicine or OncoType DX to create an FDA-approved version of their test? It seems to me they can just keep marketing them as LDTs forever?

          Comment

          Latest Articles

          Collapse

          • SEQadmin2
            Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
            by SEQadmin2



            Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

            Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
            ...
            10-14-2026, 09:55 AM
          • SEQadmin2
            New Genomics Technologies Take Aim at Long-Standing Limits
            by SEQadmin2


            Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.

            We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing
            ...
            09-28-2026, 10:25 AM

          ad_right_rmr

          Collapse

          News

          Collapse

          Topics Statistics Last Post
          Started by SEQadmin2, 10-22-2026, 11:13 AM
          0 responses
          27 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 10-22-2026, 10:48 AM
          0 responses
          20 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 10-15-2026, 10:52 AM
          0 responses
          36 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 10-14-2026, 05:39 AM
          0 responses
          43 views
          0 reactions
          Last Post SEQadmin2  
          Working...